Philips Set the Bar Low and Then Cleared It — Now Comes the Hard Part
A 70bp margin beat against management's own down-guide, an 8% order quarter stacked on another 8%, and a keyword list that has quietly stopped talking about China
PHIA.AS · Earnings Call · 2026-11-03
The guide was down. The print was up.
Three months ago Charlotte Hanneman told the market to expect a weaker third quarter. “Q3, we expect the adjusted margin to be slightly below the prior-year level as a result of inflation that is, of course, still coming through as well as unfavorable mix.” — Charlotte Hanneman, CFO · 2026-07-28 What actually arrived on 3 November was the opposite: adjusted EBITA margin up 70 basis points to 13%, expansion in all three segments, and a EUR 384 million free cash inflow nearly double last year's EUR 172 million. “Our innovations and productivity measures drove significant margin expansion across all business segments.” — Roy Jakobs, Chief Executive Officer (CEO) · 2026-11-03 Diagnosis & Treatment added 50bp to 12.3%, Personal Health 60bp to 17.7%, and Connected Care 190bp — or 340bp once you strip out a prior-year minority-interest remeasurement, which is the number that matters and the one management volunteered unprompted. Year-to-date underlying margin is up 30bp excluding the tariff refund, mid-way through a 20–70bp full-year guide that has not moved since February.
That is the real story of this quarter, and it is not the headline order number. Guidance has now been reiterated, not reset, three quarters running in an environment where peers are still marking tariffs and component costs to market.
The order-book argument finally has a date attached
Order intake grew 8% on top of 8%. Diagnosis & Treatment orders approached 20%, with both Image-Guided Therapy and Precision Diagnosis in double digits, and Precision Diagnosis' absolute order book has now expanded three consecutive quarters. The order momentum narrative has been Philips' refrain for four straight calls, and analysts have grown visibly tired of it. In July, Julien Dormois of Jefferies put the frustration plainly: “still struggling to reconcile how that is and maybe also wondering when we could see this strong order momentum transforming into sustainable -- faster growth?” — Julien Dormois, Analyst · 2026-07-28 Roy Jakobs answered with a promise: “yes, you should expect that we return to this mid-single-digit range in Q3 and beyond.” — Roy Jakobs, CEO · 2026-07-28 He delivered on the orders half of that promise.
Now he is making a bigger claim on the sales half.
In Q3, we reached the turning point where the refilling of the absolute order book comes to a level that conversion starts to hit normalized levels, because before we still had to absorb the decline and then actually added in the new.
That is a specific, falsifiable, and long-awaited claim — the distinction is between an absolute order book that had to be rebuilt from a China-damaged base and a net new order book that converts cleanly into revenue. It also carries a built-in excuse: an unexplained ultrasound manufacturing-process issue pushed shipments out of Q3 and into Q4 and early 2027, which is company-unique, unforecast, and conveniently defers proof by one to two quarters.
What is genuinely new in the customer evidence is the language of displacement. “We secured vendor of choice positions at major U.S. health systems where competitors have established relationships for more than a decade, breaking through long-standing barriers to entry.” — Roy Jakobs, Chief Executive Officer (CEO) · 2026-11-03 The keyword extractor caught it too — dislodging competition enters the company's top-30 for the first time. Connected Care is the caveat: order intake fell mid-single digit against a 20%-plus comparable, with management attributing it to bigger, more complex deals taking longer rather than to lost business, and several slipping into Q4.
What management stopped saying
Two quarters ago, centralized procurement was the single highest-ranked keyword in this company's transcript. Last quarter, cost inflation sat near the top of the list alongside it. Neither appears in the current top-30 at all. That silence is louder than anything said on the call.
China has not gone away — China sales is still a keyword, and Jakobs remains explicit that centralized procurement will keep expanding and pricing pressure with it. But it has been demoted from thesis to modifier. “We see the growth diversifying also in the rest of the world, and that's, of course, supporting this compensation, whilst China remains our focus” — Roy Jakobs, Chief Executive Officer (CEO) · 2026-11-03 — the difference being that two quarters ago, China was the thing being explained and now it is the thing being absorbed. Europe orders robust, North America growing on top of double digits, India in double digits, Latin America picking up.
Inflation, similarly, has been downgraded from a margin thesis to a footnote. Management concedes input pressures have slightly increased and that the full-year hit stays in the high double-digit millions — which, notably, is the same language used in July. The company is not pretending the pressure is gone; it is simply no longer leading with it. That shift is corroborated by the new vocabulary arriving in its place: dual source, service levels, and supply resilience, discussed in direct response to memory cost and electronic-component tightness now being driven by AI infrastructure demand — a pressure point echoed across the semiconductor-exposed reporters this week. Philips' answer is pre-buying and a second supplier network, not a price pass-through.
Respironics: the legal bill arrives, the FDA does not
The DOJ settlement is the genuine new event. A EUR 288 million provision against an agreement in principle with the U.S. Department of Justice, lifting adjusting items to EUR 353 million for the quarter, with payment assumed in Q1 2027 and the outlook explicitly excluding the State Attorneys General investigation. The legal tail is shortening; the commercial tail is not. Jakobs is blunt that a U.S. CPAP re-entry remains outside their control: “We are not in control of any timing around the return to market.” — Roy Jakobs, Chief Executive Officer (CEO) · 2026-11-03 Sleep & Respiratory still grew mid-single digits on Japan and Europe, and management repeats that delivery of targets does not depend on the U.S. coming back.
What the settlement does buy is balance-sheet room. Net debt of EUR 5.4 billion, leverage down to 1.7x from 2.2x, and a EUR 650 million green bond 2.7x oversubscribed. The obvious next question — buybacks — got the standard answer: “our fourth priority is share buybacks, which we are evaluating periodically as well.” — Charlotte Hanneman, Chief Financial Officer (CFO) · 2026-11-03 After three years of deleveraging, that ordinal ranking is starting to look like a choice rather than a constraint.
The bill of proof
Philips has spent six quarters promising that orders would become revenue. This quarter it produced the best order growth in years, the strongest margin beat against its own guide, and a legal settlement that removes the largest single known unknown from the equity story. The U.S. tariff refund — a theme now visible across a dozen industrial and healthcare reporters this season — adds roughly a point of margin and EUR 200 million of cash that is real but non-recurring. Strip that out and the underlying 30bp expansion is respectable rather than spectacular.
The case rests entirely on the fourth quarter. Management has told you the ultrasound revenue comes back, that the order book now converts at normalized rates, and that Q4 delivers the volume leverage to land 13.5–14%. Everything else this quarter was execution. The next one is credibility.